Nuveen LLC purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 124,700 shares of the biotechnology company's stock, valued at approximately $892,000. Nuveen LLC owned 0.25% of REGENXBIO as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new position in REGENXBIO during the first quarter worth $35,000. Pallas Capital Advisors LLC acquired a new position in REGENXBIO during the first quarter worth $74,000. Laurion Capital Management LP acquired a new position in REGENXBIO during the fourth quarter worth $79,000. Tower Research Capital LLC TRC boosted its holdings in REGENXBIO by 442.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company's stock worth $102,000 after purchasing an additional 10,714 shares during the last quarter. Finally, Corton Capital Inc. acquired a new position in REGENXBIO during the fourth quarter worth $103,000. Institutional investors and hedge funds own 88.08% of the company's stock.
Analyst Ratings Changes
Several brokerages recently commented on RGNX. HC Wainwright restated a "buy" rating and set a $34.00 target price on shares of REGENXBIO in a report on Tuesday, August 19th. Chardan Capital restated a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a report on Friday, August 8th. Royal Bank Of Canada reduced their target price on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Wall Street Zen lowered shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. Finally, Barclays dropped their price target on shares of REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $28.38.
Read Our Latest Report on REGENXBIO
REGENXBIO Price Performance
NASDAQ RGNX traded up $0.29 on Friday, hitting $9.71. 609,824 shares of the stock were exchanged, compared to its average volume of 643,702. The business's fifty day moving average is $8.65 and its 200 day moving average is $8.18. REGENXBIO Inc. has a 52 week low of $5.03 and a 52 week high of $13.48. The company has a market capitalization of $490.45 million, a PE ratio of -2.82 and a beta of 1.17.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The company had revenue of $21.36 million during the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. Analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.
REGENXBIO Company Profile
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
